Clinical Trials Logo

Desmoid Tumor clinical trials

View clinical trials related to Desmoid Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04871282 Active, not recruiting - Desmoid Tumor Clinical Trials

A Study of AL102 in Patients With Progressing Desmoid Tumors

RINGSIDE
Start date: March 30, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.

NCT ID: NCT03802084 Active, not recruiting - Desmoid Tumor Clinical Trials

A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor

Start date: April 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II, open-label, non-randomized, multicentre study to evaluate the clinical activity of vactosertib plus imatinib in desmoid tumor. Based on the background, TGF-β inhibition as a potential therapeutic target for desmoid tumor and convey significant implications for the clinical development. Therefore, investigator will conduct the phase II trial of vactosertib in combined with imatinib in desmoid tumor.

NCT ID: NCT03785964 Active, not recruiting - Desmoid Tumor Clinical Trials

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

DeFi
Start date: April 17, 2019
Phase: Phase 3
Study type: Interventional

This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive nirogacestat.

NCT ID: NCT02076906 Active, not recruiting - Neuroblastoma Clinical Trials

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

Start date: April 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if Magnetic Resonance guided High Intensity Focused Ultrasound ablative therapy is safe and feasible for children, adolescents, and young adults with refractory or relapsed solid tumors.